Sequence: Acetyl-KLULKLULKULKAULKLUGC(cRGDfC)-NH2
| Experiment Id | EXP000640 |
|---|---|
| Paper | Design of cyclic RGD-conjugated Aib-containing amphipathic helical peptides for targeted delivery of |
| Peptide | PI |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | yes |
| Peptide Concentration | 1.0 µM |
| Rna Concentration | 10 nM |
| Mixing Ratio | 100 |
| Formulation Format | electrostatic peptide/siRNA complex |
| Formulation Components | cRGDfC–MAP(Aib) conjugate peptide + siRNA (complex formed by electrostatic interaction) |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | A549; A549-Luc (luciferase-expressing A549) |
| Animal Model | |
| Administration Route | |
| Output Type | reporter knockdown (luciferase) |
| Output Value | 10.2% relative luciferase activity (vs control) at 24 h post-treatment |
| Output Units | |
| Output Notes | Complexation: gel retardation complete at peptide/siRNA ≥50–100. Uptake/CLSM: strong uptake in A549; uniform + punctate intracellular fluorescence; partial colocalization with LysoTracker (endosome/lysosome). RNAi: strong knockdown at 1.0 µM peptide /10 nM siRNA (ratio 100) after 8 h incubation + 24 h culture; strongest at ratio 50; ratio 20 comparable to Lipofectamine 2000. |
| Toxicity Notes | LDH release ~20% at 1.0 µM/10 nM (ratio 100) after 24 h; reduced to ~12% (ratio 50) and ~7% (ratio 20). |
| Curation Notes |